Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.7 (acetylcholinesterase)
 28,390 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of this investigation was the study of cholinesterase (ChE)-positive zones of neuromuscular synapse (NMS) in gastrocnemius and plantaris muscles of albino rats after guanethidine sympathectomy. Qualitative and morphometric characteristics of ChE-positive zones were studied, which were demonstrated using a modified thioacetic acid method in 72 control and experimental animals aged from 5 days to 3 months. It was found that in both gastrocnemius and plantaris muscles the growth of muscle fiber diameter and section area in the region of NMS was delayed after desympathization. In gastrocnemius muscle, smaller fiber diameter persisited up to the age of 3 months, while in plantaris muscle it was larger than in control animals of the same age. The differences in dimensional parameters of NMS sections were leveled off by the age of 3 months because of their accelerated growth. Desympathization resulted in the premature appearance of dystrophic changes in MNS region as compared to those developing in control animals, in which they are the features of involution processes.
 ...
PMID:[Development of neuromuscular synapse in the skeletal muscle after chemical desympathization]. 1535 89

Frontotemporal dementias (FTD) account for only 5-7% of all dementia aetiologies. However, FTD is one common form of dementia in the presenile period with a symptom onset between an age of 45 and 65 years. FTD are clinically classified into a group of rare genetic variants, the behavioural variant, primary progressive aphasias and a variant including motor neuron symptoms (FTD-MNS). In recent years the pathobiological characteristics of some FTD variants was clarified, demonstrating a pathological accumulation of TAR-DNA binding protein 43 (TDP-43) as a common pathological substrate. The revised diagnostic criteria of the behavioural variant of the FTD require at least three of six clinically discriminating features (disinhibition, apathy, loss of sympathy, perseverative behaviours, hyperorality and dysexecutive neuropsychological profile). The primary progressive aphasias are classified in a nonfluent/agrammatic variant, a logopenic variant and a semantic variant according to clinical and imaging features. Movement disorders and more precisely a Parkinsonian syndrome can be part of the FTD spectrum. Some clinical features overlap the clinical diagnosis of a progressive supranuclear paralysis and the corticobasal ganglionic degeneration. A causal therapy does not exist and medical treatment is directed at the patient's key symptoms. Different agents such as serotonin reuptake inhibitors, tricyclic antidepressants, atypical neuroleptics, carbamazepine, valproate, lamotrigine and when indicated also acetylcholinesterase inhibitors are potentially helpful. All together, theses medical treatments have a low level of evidence. Non-pharmacological therapies such as physiotherapy, occupational therapy, speech therapy and disease-specific education of the patient and their relatives are important to ensure a safe residential environment and daily routine.
 ...
PMID:[Frontotemporal dementias]. 2236 55